TOKYO–Toshiba Corporation’s (TOKYO: 6502) Storage & Electronic Devices Solutions Company today announced the launch of new two high current products, the 60V “TLP3407S” and the 100V “TLP3409S”, additions to its line-up of photorelays packaged in S-VSON4[1], the package with the industry’s smallest mounting area[2]. Mass production shipments start today.
The new products realize high voltages while retaining the features of TLP3406S, already in the line-up, which offers a 30V voltage with large on-state current rating and small size. The higher voltages realize support for DPS[3] applications, such as SoC testers, which require voltage variation for automotive ICs.
The S-VSON4 package has a 22.5% smaller mounting area than the current VSON4 package[4]. This series also pushes operating temperature to a new high, from 85°C to 110°C. It contributes to improved design efficiency by reducing the size of the tester board, increasing the number of relay circuits, and further improving integration density.
The latest Gartner market report recognizes Toshiba as the leading manufacturer of optocouplers by sales in 2015 and 2016, with 23% of sale-based market share in CY2016. (Source: Gartner “Market Share: Semiconductor Devices and Applications Worldwide, 2016” 30 March 2016.)
Toshiba will continue to deliver products that meet the needs of customers by promoting the development of a diverse portfolio of photocouplers and photorelays tailored to market trends.
Tower Semiconductor announced that it has signed silicon photonics agreements valued at $1.3 billion for…
The report is based on a survey of 150 CISOs and senior cybersecurity leaders from…
More than 200,000 voters will cast ballots using a secure and cryptographically verified online voting…
The multi-center study, involving 2,000 patients, will validate the CORA system - a breakthrough AI…
Molex, a global electronics leader and connectivity innovator, has completed the acquisition of Teramount Ltd.,…
This agreement marks the third expansion of its collaboration with AstraZeneca, building on collaborations in…